Pasar al contenido principal

EXPLOTANDO LA INFORMACION GENOMICA DEL PATOGENO PARA IDENTIFICAR NUEVOS DETERMINANTES DEL EXITO O FRACASO DEL TRATAMIENTO EN TUBERCULOSIS

PID2022-137607OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic diversity within diagnostic sputum samples is mirrored in the culture of Mycobacterium tuberculosis across different settings

  • Mariner-Llicer, Carla
  • Goig, Galo A.
  • Torres-Puente, Manuela
  • Vashakidze, Sergo
  • Villamayor, Luis M.
  • Saavedra-Cervera, Belen
  • Mambuque, Edson
  • Khurtsilava, Iza
  • Avaliani, Zaza
  • Rosenthal, Alex
  • Gabrielian, Andrei
  • Shurgaia, Marika
  • Shubladze, Natalia
  • García-Basteiro, Alberto L.
  • López, Mariana G.
  • Comas, Iñaki
11 páginas, 6 figuras, Culturing and genomic sequencing of Mycobacterium tuberculosis (MTB) from tuberculosis (TB) cases is the basis for many research and clinical applications. The alternative, culture-free sequencing from diagnostic samples, is promising but poses challenges to obtain and analyse the MTB genome. Paradoxically, culture is assumed to impose a diversity bottleneck, which, if true, would entail unexplored consequences. To unravel this paradox we generate high-quality genomes of sputum-culture pairs from two different settings after developing a workflow for sequencing from sputum and a tailored bioinformatics analysis. Careful downstream comparisons reveal sources of sputum-culture incongruences due to false positive/negative variation associated with factors like low input MTB DNA or variable genomic depths. After accounting for these factors, contrary to the bottleneck dogma, we identify a 97% variant agreement within sputum-culture pairs, with a high correlation also in the variants' frequency (0.98). The combined analysis from five different settings and more than 100 available samples shows that our results can be extrapolated to different TB epidemic scenarios, demonstrating that for the cases tested culture accurately mirrors clinical samples., This work has been supported by the following: European Research Council (ERC): H2020-ERC-COG/0800; Ministerio Español de Ciencia e Innovación: PID2022-137607OB-I00 and Fundació La Caixa: HR21-00415 received by I.C; Stop TB partnership (TB REACH): STBP/ TBREACH/GSA/W5-30 received by A.G.B; and International Science and Technology Center (ISTC): Project #G-2143; National Institute of Allergy and Infectious Diseases (NIH) received by N.S. We would like to thank Katharine Walter for reviewing the manuscript and providing her feedback, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study

  • Martínez-Martínez, Francisco José
  • Chiner-Oms, Álvaro
  • Furió, Victoria
  • Yamaoka, Yoshio
  • Dekker, John P.
  • Mégraud, Francis
  • Benejat, Lucie
  • Ducournau, Astrid
  • Giese, Alban
  • Jehanne, Quentin
  • Jauvain, Marine
  • Camargo, M. Constanza
  • Comas, Iñaki
  • Lehours, Philippe
12 páginas, 5 figuras., Background: Rising antimicrobial resistance of Helicobacter pylori is a public health challenge. Genomic-based susceptibility testing allows for the identification of resistance-associated mutations, complementing conventional diagnostics and advancing towards pathogen-based personalised therapies. Our study aimed to identify genes and mutations involved in antimicrobial resistance in H pylori and evaluate the extent to which these markers can be used as predictors of phenotypic resistance against clarithromycin and levofloxacin. Methods: In this retrospective phenotypic and genotypic observational study, we included 1011 H pylori whole-genome sequences and strains of known geographical origin from the H pylori Genome Project (HpGP) collection. We performed phenotypic clarithromycin and levofloxacin susceptibility testing on a subset of 419 HpGP strains using Etest at a centralised laboratory. A genomic analysis was conducted to identify 23S rRNA and gyrA variants and build a curated catalogue of mutations associated with resistance to clarithromycin (ie, 23S rRNA 2142A→G, 2142A→C, and 2143A→G) and levofloxacin (ie, gyrA A88V or A88P, N87K or N87I, and D91G, D91N, or D91Y). Genotype-phenotype concordance was assessed to estimate sensitivity and specificity, and the curated catalogue of resistance-associated mutations was applied to the complete HpGP set. Region-specific prevalence of resistance-associated mutations was calculated for a combined dataset including the HpGP genomes and 768 whole-genome sequences retrieved from the US National Center for Biotechnology Information Sequence Read Archive repository. Associations between resistance genotypes, H pylori subpopulations, and minimum inhibitory concentrations (MICs) were tested. Findings: Clarithromycin-resistant and levofloxacin-resistant HpGP strains were estimated with a sensitivity and specificity of 100%, with all confidence intervals ranging from 96% to 100%. The combined analysis (n=1779) found the highest prevalence of clarithromycin resistance in the western Pacific region (173 [51·2%] of 338 in southeast Asia and 75 [29·8%] of 252 in eastern Asia), north African region (seven [38·9%] of 18), and western Asian region (12 [31·6%] of 38), whereas the highest prevalence of levofloxacin resistance was found in south Asia (14 [51·85%] of 27), Central America (48 [38·7%] of 124), eastern Europe (four [36·4%] of 11), and southern Africa (three [33·3%] of nine). Similarly, 23S rRNA and gyrA genotypes are variable across H pylori subpopulations. MIC values changed depending on the specific mutation in 23S rRNA (mean clarithromycin MIC 24·61 mg/L [95% CI 12·27-36·96] for 2143A→G and 142·25 mg/L [95% CI 77·88-206·61] for 2142A→G) and gyrA (mean levofloxacin MIC 9·66 mg/L [95% CI 6·75-12·56] for mutations on codon 91, and 27·97 mg/L [95% CI 25·82-30·11] for mutations on codon 87). Interpretation: Mutations in specific genes are reliable indicators to clarithromycin and levofloxacin resistance in H pylori, making them useful markers for the development of diagnostic assays and molecular monitoring. Our results suggest that using clarithromycin and levofloxacin empirically, without previous susceptibility testing, is unsuitable in all geographical regions covered by this study., Intramural Research Program of the US National Cancer Institute, the European Research Council, and the Spanish Ministry of Science and Innovation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increasing clinical and public health role of Mycobacterium tuberculosis genomics, El papel creciente de la genómica de Mycobacterium tuberculosis en la clínica y la salud pública

  • Comas, Iñaki
6 páginas, This project received funding from the Spanish Ministry of Science and Innovation (PID2022-137607OB-I00) and the Generalitat Valenciana (Project CIPROM/2023/30)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Complete genomes reveal a refined map of Mycobacterium tuberculosis genetic diversity across evolutionary scales

  • García-Marín, Ana María
  • Torres-Puente, Manuela
  • Martínez-Priego, Llucia
  • De Marco, Griselda
  • Moreno-Molina, Miguel
  • Hunt, Martin
  • Iqbal, Zamin
  • Gil-Brusola, Ana
  • López, Mariana G.
  • González-Candelas, Fernando
  • Alonso-Del-Real, Javier
  • Comas, Iñaki
20 páginas, 8 figuras, 1 tabla., Elucidating the evolution and epidemiology of Mycobacterium tuberculosis requires comprehensive characterization of its genomic diversity; however, short-read sequencing fails to resolve part of this variation. Here, we assembled 216 complete genomes from clinical isolates in the Valencia Region, Spain, using long-read sequencing. This dataset, mostly encompassing Lineage 4, provides a refined map of M. tuberculosis genetic diversity across evolutionary scales. Complete genomes uncover a median of 312 (-1 to 792) additional SNPs per pairwise comparison, revealing an estimated evolutionary rate 1.44-fold higher than that inferred from short-read mapping. This diversity is concentrated in discrete hotspots, particularly within the pe/ppe gene family, where gene conversion is a major driver of nucleotide diversity. While most PE/PPE epitopes remain highly conserved, suggesting strong purifying selection, some involved in vaccine candidates are affected by gene conversion, with unknown consequences. At the epidemiological scale, additional resolution is gained from SNPs previously masked and newly resolved indels and structural variation, refining genetic transmission networks. Finally, at the within-host level, the use of patient-specific reference genomes allows us to capture genuine diversity during infection, showing that previous approaches led to false positive calls. Together, these findings delineate the landscape of M. tuberculosis genomic diversity and provide a framework for more accurate inference of pathogen evolution, host-pathogen interactions, and transmission dynamics., This project received funding from the European Research Council under the European Union’s Horizon 2020 Research and Innovation Programme (Grant 101001038, TB-RECONNECT) awarded to I.C. Additional support was provided by the Spanish Ministry of Science and Innovation (PID2022-137607OB-I00) and the Generalitat Valenciana (Project CIPROM/2023/30), both also awarded to I.C., and PID2021-127919OB-I00 and PID2024-155977OB-I00 to FGC. AGM has been supported by a ‘Formación de Profesorado Universitario’ (FPU) grant (FPU19/ 04562) from the Spanish Ministry of Universities, and the Health Research 2021 Programme (TB-TARGET_HR21-00415) by LaCaixa Foundation. Work in IC’s laboratory is further supported by the European Union’s Next Generation, through CSIC’s Global Health Platform (PTI Salud Global). JAR is hired under the Generation D initiative, promoted by Red.es, an organisation attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts (MMT24-PTI-SG-01), financed by the Recovery, Transformation, and Resilience Plan through the European Union’s Next Generation funds., Peer reviewed, Sin experimentacion animal ni uso de NAMs
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model

  • Campo-Pérez, Víctor
  • Guallar-Garrido, Sandra
  • Cabrera-Rubio, Raúl
  • Herrero-Abadía, Paula
  • Seguí-Moll, Arnau
  • Torres-Puente, Manuela
  • Cano-Jiménez, Pablo
  • Comas, Iñaki
  • Torrents, Eduard
  • Julián, Esther
13 páginas, 8 figuras, The bladder microbiota may influence tumor progression and responses to intravesical therapies, yet the effects of Mycobacterium bovis BCG instillations on bladder and gut microbiota remain unexplored. This study evaluates, for the first time, the impact of M. bovis BCG and Mycobacterium brumae, a non-pathogenic immunomodulator, on microbiota composition in bladder tissue and cecal stool of healthy and tumor-bearing mice. Mycobacterial instillations increased gut microbial richness but reduced Actinobacteria. In tumor-bearing mice, Muribaculaceae and Bacteroidaceae were enriched, while M. bovis BCG reduced Muribaculaceae and increased Rikenellaceae. In the bladder, M. brumae instillations favored Staphylococcaceae in healthy mice, while Enterococcaceae dominated most groups except M. bovis BCG-treated tumor-bearing mice. Escherichia/Shigella decreased in mycobacteria-treated tumor-bearing mice, while Burkholderia was more prevalent in untreated bladders. Notably, M. brumae increased stool alpha diversity, whereas M. bovis BCG reduced bladder richness. These findings reveal that intravesical mycobacterial therapy modulates microbiota composition across body sites, underscoring the complex host-tumor-immunotherapy interplay., R.C.-R. thanks Generalitat-Valenciana (GVA) for the grant Plan GenT-Talent Attraction program (CDEIGENT 2020). V.C.-P. and A.S.-M. acknowledge AGAUR (Generalitat de Catalunya) for their support through the FI fellowship (2019 FI_B 00320 and 2022 FI_B 00822) during the period in which this work was carried out. This research was funded by grants PID2021-122331OB-I00, PID2021-125801OB-100, PID2024-158933OB-I00, PLEC2022-009356, PID2022-137607OB-I00, and PDC2022-133577-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE, MycoNET (RED2018-102677-T and RED-153634-T) and the CERCA program and AGAUR-Generalitat de Catalunya (2021SGR-01545 and 2021SGR-0092). RCR thanks Generalitat-Valenciana for the grant Plan GenT project (CDEIGENT 2020-02) and the Spanish government MCIN/AEI to the IATA-CSIC as Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/MCIN/AEI/10.13039/501100011033). E.T. is a researcher of the ICREA Academia 2025 program. E.J. is a Serra-Húnter fellow.